Health News from Medical News Today: Seaside Therapeutics Initiates Pivotal Phase 3 Study Of STX209 In Fragile X Syndrome

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Seaside Therapeutics Initiates Pivotal Phase 3 Study Of STX209 In Fragile X Syndrome 3 Jun 2011, 5:00 pm Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 (arbaclofen) on social impairment in adolescents and adults (ages 12 to 25) with fragile X syndrome. A second study in children (ages 5 to 11) is expected to begin in early summer. STX209 is an oral selective gamma-amino butyric acid type B (GABA-B) receptor agonist... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.